期刊文献+

Tagitinin D诱导人肝癌HepG2细胞凋亡的作用机制研究 被引量:2

The mechanism of tagitinin D-induced apoptosis in HepG2 cells
下载PDF
导出
摘要 菊科植物肿柄菊中富含tagitinin D,该化合物具有较强的抑制肿瘤细胞的作用。本文研究了tagitinin D诱导HepG2细胞凋亡的作用机制。采用克隆形成实验检测细胞成瘤能力、流式细胞仪测细胞周期及凋亡,DCFH-DA探针测活性氧的水平及Western blot检测ER stress相关蛋白表达。结果表明,tagitinin D抑制细胞成瘤,将细胞周期阻滞在G2/M期,诱导细胞凋亡,使细胞内ROS积累,增加了ER stress伴侣蛋白PDI、Calnexin、Ero1-Lα、Bip的表达并激活了IRE1α和PERK信号通路。综上所述tagitinin D依赖于ROS途径激活ER stress诱导细胞凋亡。 Tagitinin D was identified as one of the main compounds present in Asteraceae,which exhibited anti-tumor activities.To explore the mechanism of apoptosis in HepG2 cells induced by tagitinin D,colony formation assay was used to detect the cell proliferation ability.Then the cell cycle and apoptosis were checked by flow cytometry,and the changes of reactive oxygen species(ROS) levels was detected by DCFH-DA,and ER stress-related protein expression levels were determined using Western blot assay.The results showed that tagitinin D increased ROS levels,inhibited the cell proliferation,arrested the cell cycle in the G2/M phase,and induced apoptosis in HepG2 cells.ER stress signaling pathway related protein levels such as PDI,Calnexin,Ero1-Lα,Bip,IRE1-Lα,and p-eIF2α are increased.In summary,all the data suggested tagitinin D induced ROS which further elicited ER stress response and led to apoptosis in HepG2 cells.
作者 杨珊 韦睿然 陈远志 杨旭 王娟 杨杏芝 何志旭 丁骁 YANG Shan;WEI Rui-ran;CHEN Yuan-zhi;YANG Xu;WANG Juan;YANG Xing-zhi;HE Zhi-xu;DING Xiao(Department of Immunology,Basic Medical College,Tissue Engineering and Stem Cell Research Center,Guizhou Medical University,Guiyang 550004,China;State Key Laboratory of Phytochemistry and Plant Resources in West China,Kunming Institute of Botany,Chinese Academy of Sciences,Kunming 650201,China)
出处 《天然产物研究与开发》 CAS CSCD 北大核心 2020年第3期359-364,共6页 Natural Product Research and Development
基金 国家自然科学基金(81703393)。
关键词 tagitinin D ROS 凋亡 ER stress信号通路 tagitinin D ROS apoptosis ER stress signaling pathway
  • 相关文献

参考文献2

二级参考文献115

  • 1Steel JL, Nadeau K, Olek M, Carr BI. Preliminary results of anindividually tailored psychosocial intervention for patients withadvanced hepatobiliary carcinoma. J Psychosoc Oncol 2007; 25:19-42 [PMID: 19341012 DOI: 10.1300/J077v25n03_02].
  • 2Farazi PA, DePinho RA. Hepatocellular carcinoma pathogenesis:from genes to environment. Nat Rev Cancer 2006; 6: 674-687[PMID: 16929323 DOI: 10.1038/nrc1934].
  • 3Lopez PM, Villanueva A, Llovet JM. Systematic review: evidencebasedmanagement of hepatocellular carcinoma--an updatedanalysis of randomized controlled trials. Aliment PharmacolTher 2006; 23: 1535-1547 [PMID: 16696801 DOI: 10.1111/j.1365-2036.2006.02932.x].
  • 4Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A,Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L.Liver transplantation for the treatment of small hepatocellularcarcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104].
  • 5Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A,Ascher NL, Roberts JP. Liver transplantation for hepatocellularcarcinoma: expansion of the tumor size limits does not adverselyimpact survival. Hepatology 2001; 33: 1394-1403 [PMID:11391528 DOI: 10.1053/jhep.2001.24563].
  • 6Kwon CH, Kim DJ, Han YS, Park JB, Choi GS, Kim SJ, Joh JW,Lee SK. HCC in living donor liver transplantation: can we expandthe Milan criteria- Dig Dis 2007; 25: 313-319 [PMID: 17960066DOI: 10.1159/000106911].
  • 7Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, Ogawa K,Sakamoto S, Ogura Y, Egawa H, Tanaka K, Uemoto S. Expansionof selection criteria for patients with hepatocellular carcinomain living donor liver transplantation. Liver Transpl 2007; 13:1637-1644 [PMID: 18044766 DOI: 10.1002/lt.21281].
  • 8Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, AishimaS, Terashi T, Shimada M, Maehara Y. Extended indication forliving donor liver transplantation in patients with hepatocellularcarcinoma. Transplantation 2007; 83: 893-899 [PMID: 17460559DOI: 10.1097/01.tp.0000259015.46798.ec].
  • 9Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, AscherNL, Roberts JP. Liver transplantation for hepatocellular carcinoma:analysis of survival according to the intention-to-treat principleand dropout from the waiting list. Liver Transpl 2002; 8: 873-883[PMID: 12360427 DOI: 10.1053/jlts.2002.34923].
  • 10Roayaie K, Feng S. Allocation policy for hepatocellular carcinomain the MELD era: room for improvement- Liver Transpl 2007; 13:S36-S43 [PMID: 17969067 DOI: 10.1002/lt.21329].

共引文献83

同被引文献19

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部